Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma
AuthorWechsler, Michael E
Szefler, Stanley J
Ortega, Victor E
Pongracic, Jacqueline A
Lima, John J
Krishnan, Jerry A
Kunselman, Susan J
Bleecker, Eugene R
Bacharier, Leonard B
Blake, Kathryn V
Cabana, Michael D
Chmiel, James F
Fitzpatrick, Anne M
Jackson, Daniel J
LaForce, Craig F
Lazarus, Stephen C
Lemanske, Robert F
Meyers, Deborah A
Moore, Wendy C
Olin, J Tod
Peters, Stephen P
Robison, Rachel G
Smith, Lewis J
Sorkness, Christine A
AffiliationUniv Arizona Hlth Sci
MetadataShow full item record
PublisherMASSACHUSETTS MEDICAL SOC
CitationWechsler, M. E., Szefler, S. J., Ortega, V. E., Pongracic, J. A., Chinchilli, V., Lima, J. J., ... & Bacharier, L. B. (2019). Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. New England Journal of Medicine, 381(13), 1227-1239.
JournalNEW ENGLAND JOURNAL OF MEDICINE
RightsCopyright © 2019 Massachusetts Medical Society. All rights reserved.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractBackground: Morbidity from asthma is disproportionately higher among black patients than among white patients, and black patients constitute the minority of participants in trials informing treatment. Data indicate that patients with inadequately controlled asthma benefit more from addition of a long-acting beta-agonist (LABA) than from increased glucocorticoids; however, these data may not be informative for treatment in black patients. Methods: We conducted two prospective, randomized, double-blind trials: one involving children and the other involving adolescents and adults. In both trials, the patients had at least one grandparent who identified as black and had asthma that was inadequately controlled with low-dose inhaled glucocorticoids. We compared combinations of therapy, which included the addition of a LABA (salmeterol) to an inhaled glucocorticoid (fluticasone propionate), a step-up to double to quintuple the dose of fluticasone, or both. The treatments were compared with the use of a composite measure that evaluated asthma exacerbations, asthma-control days, and lung function; data were stratified according to genotypic African ancestry. ResultsWhen quintupling the dose of fluticasone (to 250 mu g twice a day) was compared with adding salmeterol (50 mu g twice a day) and doubling the fluticasone (to 100 mu g twice a day), a superior response occurred in 46% of the children with quintupling the fluticasone and in 46% of the children with doubling the fluticasone and adding salmeterol (P=0.99). In contrast, more adolescents and adults had a superior response to added salmeterol than to an increase in fluticasone (salmeterol-low-dose fluticasone vs. medium-dose fluticasone, 49% vs. 28% [P=0.003]; salmeterol-medium-dose fluticasone vs. high-dose fluticasone, 49% vs. 31% [P=0.02]). Neither the degree of African ancestry nor baseline biomarkers predicted a superior response to specific treatments. The increased dose of inhaled glucocorticoids was associated with a decrease in the ratio of urinary cortisol to creatinine in children younger than 8 years of age. Conclusions: In contrast to black adolescents and adults, almost half the black children with poorly controlled asthma had a superior response to an increase in the dose of an inhaled glucocorticoid and almost half had a superior response to the addition of a LABA. (Funded by the National Heart, Lung, and Blood Institute; BARD ClinicalTrials.gov number, NCT01967173.)
Note6 month embargo; published online: 26 September 2019
VersionFinal published version
SponsorsNational Heart, Lung, and Blood Institute, United States Department of Health & Human Services, National Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)
- Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
- Authors: Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM, Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute.
- Issue date: 2010 Mar 18
- Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
- Authors: Vogelmeier C, Naya I, Ekelund J
- Issue date: 2012 Jul 1
- Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.
- Authors: Płoszczuk A, Bosheva M, Spooner K, McIver T, Dissanayake S
- Issue date: 2018 Jan-Dec
- Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma.
- Authors: Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ, VESTRI Investigators.
- Issue date: 2016 Sep 1